Meet a man affected by Dominantly Inherited Alzheimer’s Disease and learn why he participates in the DIAN clinical trial.
The DIAN-TU has launched the world’s first prevention trial for at-risk families with DIAD. This interventional therapeutic trial focuses on drugs that could potentially change the course of the disease. It evaluates the safety, tolerability and effectiveness of these drugs and will determine if they can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.
The clinical trial is designed and coordinated by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), based at Washington University School of Medicine in St. Louis.
Trial name: DIAN-TU-001: A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease.
Principal Investigator: Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis.
How to enroll
To be considered for this trial